Source: Annual Congress 2012 - Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Lötvall, E. Bleecker, W. Busse, P. O‘Byrne, A. Woodcock, E. Bateman, E. Kerwin, S. Stone, R. Forth, L. Jacques (Gothenburg, Sweden; Winston-Salem, Madison, Medford, Durham, United States Of America; Hamilton, Canada; Manchester, Uxbridge, United Kingdom; Cape Town, South Africa). LATE-BREAKING ABSTRACT: Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in patients with persistent asthma: A 24-week randomised trial. Eur Respir J 2012; 40: Suppl. 56, 2123

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 LATE-BREAKING ABSTRACT: ENERGITO: Efficacy and safety of once-daily combined tiotropium + olodaterol versus twice-daily combined fluticasone propionate + salmeterol Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 Mometasone furoate/formoterol (mf/f) combination treatment in patients with moderate-to-severe asthma: findings from a 1-yr safety trial Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021 Year: 2021 LATE-BREAKING ABSTRACT: TRILOGY: a phase III study to evaluate the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) in COPD patients Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 A multi-centre doubleblind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate/fluticasone propionate combination product versus prednisolone Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003 Treatment of asthmatic patients with beclomethason dipropionate (BDP) or budesonide(B)-comparative, randomized, double blind clinical study Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003 Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) for 24 weeks in persistent asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Efficacy and safety of once-daily (OD) fluticasone furoate (FF) 50mcg over 24 weeks in adults and adolescents with persistent asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study Source: Annual Congress 2009 - New bronchodilators Year: 2009 Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 LATE-BREAKING ABSTRACT: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: the LANTERN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Comparison of efficacy and safety of two HFA formulations of fluticasone propionate; a double-blind, randomised, multicentric, parallel group study in patients with persistent moderate asthma Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Late Breaking Abstract - Dose responses for topical efficacy and systemic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects. Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 Seasonality of asthma exacerbations: efficacy of fluticasone furoate/vilanterol 100/25µg (FF/VI) vs fluticasone furoate 100µg (FF) alone Source: International Congress 2017 – Asthma management Year: 2017 Indacaterol once-daily improves symptom control in COPD patients: a 52-week evaluation vs placebo (pbo) and formoterol (for) Source: Annual Congress 2009 - New bronchodilators Year: 2009 Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in adults and adolescents with moderate-to-severe persistent asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Safety and efficacy of fluticasone furoate/vilanterol trifenatate (FFVI) in COPD patients Source: Annual Congress 2010 - Bronchodilators in airways disease Year: 2010 Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study Source: Eur Respir J 2016; 48: 1030-1039 Year: 2016